Teijin Limited

Yutaka Mitzushima

Teigin Limited

Taisho Pharmaceutical

Hirofumi Tanabe

Kenichiro Kataoka

Hisao Yamaguchi

Tatsuki Shiota

Takumi Takeyasu

Tsutomu Mochizuki

Mikio Ota

Takashi Matsunaga

Yoshiaki Igarashi

Shigeru Nakayama

Kentaro Fujinaga

Yoji Yamamoto

Kiyoyuki Sakon

Hiroaki Mitsuhashi

Masatoshi Kano

Toshinobu Murakami

Masahiko Narasaki

Kazuoki Tsuruta

A medicinal composition containing one or more compounds selected from the compounds represented by the following formula (I), salts of these compounds, solvates of these compounds and solvates of these salts and being capable of reducing the contact of the compounds with the components in the bile or pancreatic juice.

Release-regulating preparations comprising biphenyldiamine derivatives

Pharmaceutical composition for treating peripheral circulation disorders

A benzopyran derivative represented by the formula (I) or its pharmaceutically acceptable salt: ##STR1## wherein either one of X and Y stands for the following formula ##STR2## and the other one of X and Y and R.sup.1 -R.sup.10 stand for various substituents, and ACAT inhibitor, anti-hyperlipidemia agent and anti-atherosclerosis agent compositions containing the same as an active ingredient.

Benzopyran derivative, process for producing the same and pharmaceutical

Pharmaceutical compositions containing a benzoxazole compound and a 2,3-dihydrobenzofuran compound represented by the following formula (I) and its pharmaceutically acceptable salt: ##STR1## In the formula, any one of P, Q, R and S is a group represented by the formula: ##STR2## and R.sub.1, R.sub.2 and the reining three substituents out of the substituents P to S each independently stand for various substituents. These compositions are used as an ATCAT inhibitor or for treating hyperlipidemia and atherosclerosis.

Benzoxa condensed ring compounds, process for producing the same and

Growing community of inventors

Tokyo, Japan

Hirofumi Tanabe